Active, not recruiting
May 27, 2020
May 10, 2021
To assess the tolerability, safety, and pharmacokinetics (PK) of ONO-7913 in patients with advanced or metastatic solid cancers and explore its efficacy and biomarkers.
|Experimental: ONO-7913 as a Single Agent
ONO-7913 will be administered by intravenous continuous infusion during the designated time.
Inclusion Criteria: 1. Patients with histologically or cytologically confirmed advanced or metastatic solid tumors 2. ECOG Performance Status of 0-1 3. Patients with life expectancy of at least 3 months Exclusion Criteria: 1. Patients with multiple cancers 2. Patients with history of serious allergy
Ono Pharmaceutical Co. Ltd
Study Chair: Kazuhiro Nakabayashi Ono Pharmaceutical Co. Ltd